EXTON, Pa., Nov. 7, 2011 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
The NIH has awarded Kensey Nash Corporation a two-year, $1.9 million Phase II SBIR grant to further investigate the use of a bioadhesive surgical mesh for applications in tendon repair procedures. The Company will develop and evaluate the ability of its proprietary bioadhesive technology to augment standard sutured tendon repair. Ultimately, the use of a bioadhesive device for this surgical application is expected to create a stronger repair, thereby enhancing repair efficacy and improving patient outcomes.
“Over the past twenty-five years Kensey Nash has developed a broad range of innovative products and technologies that have benefitted patients worldwide. This grant will allow us to explore new applications for our recently acquired adhesive technology in combination with our other extracellular matrix, collagen, and polymer based biomaterials to develop new solutions for existing medical problems,” commented Doug Evans, Chief Operating Officer.
About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technologies. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products which are sold through strategic partners in multiple medical markets, including the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets. For more information, visit www.kenseynash.com.
SOURCE Kensey Nash Corporation
